LKT Labs

Biochemicals for Life Science Research

Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $127.60 In stock
100 mg $317.50 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7
Purity

≥97%
Formula

C26H46N2O
Formula Wt.

402.66
IUPAC Name

C26H46N2O
Synonym

Bebuxine, Cyclovirobuxine
Melting Point

219-224°C
Appearance

White crystal

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF
Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • Z0944

    ZCL-278

    Cdc42 inhibitor.

    ≥98%
  • K4401

    KL-1 Peptide

    Peptide, c-Kit ligand fragment.

    ≥95%
  • A761003

    AT-7519 Hydrochloride

    ATP competitive CDK inhibitor.

    ≥98%
  • D1694

    Dexamethasone Acetate Monohydrate

    Steroid; glucocorticoid agonist.

    ≥98%
  • B1545

    Benzalkonium Bromide

    Quaternary ammonium cationic surfactant, dissoc...

    ≥95%
  • G4481

    Glucagon-like Peptide I Amide (7-36), human

    Endogenous peptide hormone, GLP-1 fragment, inv...

    ≥95%
  • O4917

    Omeprazole

    H+/K+ ATPase inhibitor.

    ≥98%
  • G3459

    Ginsenoside Rg2

    Triterpene saponin found in species of Panax.

    ≥98%
  • P5745

    Polygalic Acid

    Saponin found in Polygala.

    ≥97%
  • C0367

    S-(−)-Carbidopa Monohydrate

    Hydrazine; L-amino acid decarboxylase inhibitor...

    ≥98%
  • P577520

    Ponatinib

    pan-Bcr-Abl tyrosine kinase inhibitor.

    ≥99%
  • R0161

    Rapamycin

    Macrolide originally produced by Streptomyces; ...

    ≥99%
  • A4498

    Alytesin

    Antimicrobial peptide found in amphibians.

    ≥95%
  • J5237

    JNJ-26854165

    MDM2 inhibitor.

    ≥98%
  • P7021

    Prednisone Acetate

    Synthetic prednisolone prodrug; glucocorticoid ...

    ≥98%
  • D1624

    Deflazacort

    Oxazoline; glucocorticoid agonist.

    ≥98%
  • A6823

    Argatroban

    Thrombin inhibitor.

    ≥98%
  • A7460

    Asparaginase

    Catalyzes hydrolysis of asparagine.

    ≥98%
  • P2858

    4-α-Phorbol-12-myristate-13-acetate

    Negative control for PKC activation.

    ≥98%
  • T0142

    TAK-733

    MEK inhibitor.

    ≥98%